Abberant overexpression of PTK6 has been described in other types of cancers and it has previously been suggested that PTK6 may be a useful biomarker to predict outcomes of patients with various cancers including breast, head and neck, ovarian and lung cancers [6], [12], [30]–[33]. Here, PTK6 is linked to cancer.